Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1980 2
1983 2
1984 3
1985 3
1988 1
1989 2
1990 2
1991 1
2001 1
2004 1
2009 2
2011 2
2012 1
2013 1
2014 2
2015 2
2016 3
2017 5
2018 6
2019 3
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

48 results
Results by year
Filters applied: . Clear all
Page 1
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Kappos L, et al. Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Lancet. 2018. PMID: 29576505 Clinical Trial.
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS; Evobrutinib Phase 2 Study Group. Montalban X, et al. N Engl J Med. 2019 Jun 20;380(25):2406-2417. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10. N Engl J Med. 2019. PMID: 31075187 Clinical Trial.
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group. Chitnis T, et al. N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149. N Engl J Med. 2018. PMID: 30207920 Free article. Clinical Trial.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.
Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.
Chataway J, Martin K, Barrell K, Sharrack B, Stolt P, Wraith DC; ATX-MS1467 Study Group. Chataway J, et al. Neurology. 2018 Mar 13;90(11):e955-e962. doi: 10.1212/WNL.0000000000005118. Epub 2018 Feb 21. Neurology. 2018. PMID: 29467307 Clinical Trial.
Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators. Calabresi PA, et al. Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30. Lancet Neurol. 2014. PMID: 24794721 Clinical Trial.
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators. Cadavid D, et al. Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5. Lancet Neurol. 2019. PMID: 31285147
[Primary progressive multiple sclerosis: current issues of timely diagnosis].
Popova EV, Boyko AN, Barabanova MA, Antipova LN, Bakhtiyarova KZ, Belova AN, Solovieva VS, Belskaya GN, Lukashevich IG, Nikolaeva LI, Volkova LI, Turova EL, Kraeva AV, Goncharova ZA, Malkova NA, Poverennova IE, Sivertseva SA, Zhelnin AV, Trushnikova TN, Khabirov FA, Khaibullin TI. Popova EV, et al. Among authors: Khabirov FA. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(10. Vyp. 2):35-40. doi: 10.17116/jnevro201711710235-40. Zh Nevrol Psikhiatr Im S S Korsakova. 2017. PMID: 29359731 Review. Russian.
[Clinical recommendations on the use of teriflunomide].
Alifirova VM, Bakhtiyarova KZ, Belova AN, Bisaga GN, Boiko AN, Boiko OV, Vlasov YV, Volkova LI, Goncharova ZA, Davydovskaya MV, Zakharova MN, Kotov SV, Lashch NY, Malkova NA, Petrov AM, Popova EV, Sivertseva SA, Sokolova IA, Spirin NN, Stolyarov ID, Streknev AG, Totolyan NA, Khachanova NV, Sherman MI, Shmidt TE, Khabirov FA, Yampol'skaya-Gosteva IA. Alifirova VM, et al. Among authors: Khabirov FA. Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(10 Pt 2):98-104. doi: 10.17116/jnevro201611610298-104. Zh Nevrol Psikhiatr Im S S Korsakova. 2016. PMID: 28139617 Russian. No abstract available.
48 results
Jump to page
Feedback